title: Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma.
abstract: We report a rare complication of a secondary malignant solid tumor in two patients with non-Hodgkin's malignant lymphoma who developed lung adenocarcinoma after treatments with combination chemotherapies. The first was a case of primary malignant lymphoma of the cervical spinal cord which had been previously treated with radiation to the spinal lesion and combination chemotherapies and entered complete remission. The patient was further treated for relapse with autologous bone marrow transplantation preconditioned with high-dose chemotherapy. Lung adenocarcinoma developed 5.5 years after the initial diagnosis. The second case of malignant lymphoma of lymph nodes did not respond to conventional combination chemotherapies and did not enter remission. Lung adenocarcinoma developed 1 year after the initial diagnosis. The two patients died of lung carcinoma. The clinical profiles of these cases are presented and the causal relationship of primary malignant neoplasms to the second malignant neoplasms is discussed.
authors.affiliation: Department of Medicine, Yamaguchi Prefecture Central Hospital, Hofu, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Shinohara
authors.forename: K
authors.initials: K
authors.lastname: Takeda
authors.forename: N
authors.initials: N
authors.lastname: Kameda
authors.forename: K
authors.initials: K
authors.lastname: Katsuki
authors.forename: K
authors.initials: K
authors.lastname: Ariyoshi
authors.forename: T
authors.initials: T
authors.lastname: Kamei
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D003907:Dexamethasone / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008175:Lung Neoplasms / Q000209:etiology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011241:Prednisone / Q000009:adverse effects; D013120:Spinal Cord Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate